
What do the 20s have in store for the pharma industry?
The pharmaceutical industry is always evolving to keep up with the latest developments. In the 2010s we saw a new American president and Brexit shake up the global economy, creating ripples across every industry. The 20s have been no different. Advances in technology, increasing regulatory scrutiny and changing consumer behaviour are just a few of the elements redefining healthcare.
There’s no doubt that this decade will be an exciting one for pharma professionals, with impressive growth in the market, and more and more companies taking advantage of the possibilities that new technology offers to make groundbreaking discoveries and develop new avenues within healthcare.
So here are seven things to keep your eyes on.
1. High stocks and moderate growth in the market
The last five years have been a rocky road for the pharma industry, with market uncertainty and changes in U.S. tax laws slowing down growth. Couple this with the outbreak of Covid-19 and it was a storm that many pharma companies never even imagined they’d have to weather.
Unlike many less fortunate industries, the pharmaceutical market has seen significant growth since the start of the Covid-19 pandemic where we saw new demand for drugs, vaccines, and other medical products. Not to mention the record-breaking timescale for vaccine development that had the entire world holding its breath.
According to McKinsey, the pandemic forced companies to reimagine their organisational strategies. The long-term effects of this worldwide crisis are yet to be seen. Will the pharma market be one of the few to emerge even stronger than before?
2. Emerging markets
The pharmaceutical market is also experiencing somewhat of a change, as new countries begin to emerge onto the global scene. Though America is expected to dominate the market over the next five or so years, accounting for 45% of the total market value, China is making headway in the effort to be seen as a major player too. With a huge population, new measures passed by the government to encourage a faster process of drug approvals, and new technologies which make it easier to connect patients with doctors. A recent report shows that its biopharma market value alone grew from $3 billion to $380 billion in just five years.
However, other countries are also becoming forces to be reckoned with, such as Saudi Arabia, India, and Brazil. As the demand for healthcare products and services is expected to increase, so will the opportunities for other nations. There’s no telling what countries could hold the greatest stake by the end of the decade.
3. Speciality diseases will become more popular
Though oncology and diabetes have been earmarked as the top areas for growth within the pharma industry in 2018, rare and speciality-disease drugs are also on the rise and will continue to dominate the market throughout the 20s. In the past, many companies have relied on large disease populations for revenue, however, today many are making the switch to developing treatments for rare diseases. Due to favourable regulations across the U.S. and Europe, orphan drugs can be some of the most expensive drugs on the market, with a patent that lasts fifty years and can bring in millions in revenue for the company that develops and sells them. With the speciality-disease drug market reaching a value of $195 million in 2022, it’s proving to be a strong contender against the mass-distribution drug market, particularly in regards to the return on investment.
4. Big data gets even bigger
Big data was the buzzword of the decade in the 2010s. So has it delivered on its promise to transform the industry? You only need to look at how Big data is used in pharma to get your answer. Think about drug discovery, clinical trials, real-world evidence and precision medicine. Not one of these avenues would have developed to the point that it’s at without the application of big data. Those are just four major areas that have pushed the pharmaceutical industry forward in the last few years and are pegged to drive it even further over the next few years.
With the potential to improve the efficiency of clinical trials, and generate vast amounts of data, both in trials and from the healthcare apps that patients are increasingly using to monitor their health, big data is proving to be a goldmine for researchers too. There is no doubt that it has left its mark on the global market.
5. Technical breakthroughs in nanotechnology and genetic engineering
With vast leaps in technology have come new ways of researching and developing groundbreaking medical treatments. Recent years have seen groundbreaking breakthroughs in areas like gene editing, with CAR-T and CRISPR-Cas9 technologies which are capable of editing genes and DNA moving one step closer to mass-market use - and thus the potential of being able to address and cure previously incurable diseases like Cystic Fibrosis and other extremely complex health conditions such as sickle cell disease and muscular dystrophy. Over the next decade, expect more investment and more research to be made in this area than ever before.
6. The continued rise of generic drugs
Recent estimates show that the global generics drug market is expected to hit $574.63 billion by the end of the decade. The rise of generic drugs has dramatically impacted the pharmaceutical market, leading to increased competition, lower prices for consumers, and opportunities for new entrants.
As more generic drugs enter the market, brand-name drug manufacturers can expect to see a drip in revenue. For those that rely on a few blockbuster drugs for the majority of their revenue, this will hit them particularly hard. But for the global pharmaceutical market and the consumer, this can only be a good thing. Heightened competition makes healthcare more affordable and accessible, which is particularly welcome news for patients with chronic conditions who require ongoing medication.
7. Patient-oriented healthcare
According to Deloitte, the gap between the patient and their data is closing, creating a “hospital without walls”.
One of the biggest changes that technology is bringing to the pharmaceutical market, however, is increased patient contact. The internet, smartphones and apps now mean that healthcare can be accessed anywhere, at any time: as a result, many firms are moving towards a new approach for engaging their patients, where their customers are better informed about the drugs that they are taking and given better tools to manage their subscriptions.
Deloitte’s 2022 Global Health Care Outlook report highlights how an uptick in healthcare cloud investment is not only improving care for patients, but it’s also enabling them to imagine a better return on investment. More profitability within the market means greater R&D budgets and, hopefully, bigger and better innovations in the years to come.
More innovation and growth
Big changes are on the horizon in pharma. From the market opening up to advances being made in everything from gene-editing technology to more sophisticated cloud-based solutions that inspire better communication between patient and company, pharma is moving with the times and innovating its client offering. The 20s will undoubtedly continue to be an interesting decade for the global market.
Interest piqued? Pharmaceuticals is one of the most exciting industries to work in, and we at IQVIA pride ourselves on matching the best talent to the most exciting job opportunities worldwide. Take a look at our medical sales jobs, browse patient-centric roles or explore our other areas of work to find a position that aligns with your skills.
Find out more about life at IQVIA
Did you know IQVIA has
Excellent work-life balance
and is committed to this kind of culture
Did you know IQVIA has
86,000+ employees
from clinicians to data scientists each transforming healthcare in 100+ countries
Did you know IQVIA has
56+ petabytes of unique data
including 1.2B+ non-identified patient records
Did you know IQVIA has
4,600 data scientists
including statisticians and analytics developers
Did you know IQVIA has
1,900+ epidemiologists
and real world insight experts
Did you know IQVIA cares about
Health and Wellbeing
for all its employees
Did you know IQVIA has
Countless development opportunities
for personal and professional growth
Did you know IQVIA has
Excellent work-life balance
and is committed to this kind of culture
Did you know IQVIA has
56+ petabytes of unique data
including 1.2B+ non-identified patient records
Did you know IQVIA has
86,000+ employees
from clinicians to data scientists each transforming healthcare in 100+ countries
Did you know IQVIA has
4,600 data scientists
including statisticians and analytics developers
Did you know IQVIA has
Countless development opportunities
for personal and professional growth
Did you know IQVIA cares about
Health and Wellbeing
for all its employees
Did you know IQVIA has
1,900+ epidemiologists
and real world insight experts
Related jobs
We are sorry but your search has returned no results.
Please try some of the links below to find what you are looking for:
Since joining IQVIA I have had unrivalled support and development from my manager to enable me to aspire to move into secondary care. I feel like my career is strongly supported by my manager in order to maximise my potential.
IQVIA has been behind my development to become a MSL. The contracts that I have worked on have allowed me to push clinical projects with a recent opportunity to manage a pilot scheme integrating e-detailing into an established field based team. The result was an increase in sales.
A quick note to say thank you for your time this morning discussing my future career options. As you know I was feeling very conflicted about the right decision. Discussing the role with you gave me chance to clarify what is important to me.
Once again I cannot thank you enough for not only approaching me with this opportunity but also for all the support you’ve given me along the way!
Just following on from the amazing news I got yesterday I wanted to say a really special thank you for all the help and support you have provided throughout the entire recruitment process.
A quick note to say thank you for your time this morning discussing my future career options. As you know I was feeling very conflicted about the right decision. Discussing the role with you gave me chance to clarify what is important to me.
IQVIA Related insights

Teaser
Medical Sales & ServicesContent Type
ArticlePublished
24/10/2024
Summary
We caught up with Diana Heres, a Service Development Executive at IQVIA Interface, on her career development journey with us so far. Diana shares her journey to help answer questions such as “How do
by
Ruth Lynn

Teaser
GeneralContent Type
ArticlePublished
08/10/2024
Summary
Recently, we interviewed Corinne Scott, Client Services Manager at IQVIA for her insight into how to decide a career change. Corinne shared her own journey and valuable advice with us to help answer
by
Corinne Scott

Teaser
SalesContent Type
ArticlePublished
04/10/2024
Summary
Virtual Sales has a growing presence in the healthcare and medical solutions industry, especially since the pandemic. Virtual Sales is set to be the new normal, even as we’ve emerged on the other side

Teaser
GeneralContent Type
ArticlePublished
27/09/2024
Summary
Kickstarting or switching your career is only made easier by having solid technical skills under your belt. Technical skills are expertise and specialised knowledge that you enhance throughout your c
by
Ruth Lynn

Teaser
SalesContent Type
ArticlePublished
18/09/2024
Summary
If you’re a recent or soon-to-be graduate of biomedical science, and have realised that a laboratory-based career may not be the right direction for you, you may be wondering what other career opti
by
Tracey Smith

Teaser
Medical Sales & ServicesContent Type
ArticlePublished
17/09/2024
Summary
Stepping into any role in the healthcare sector comes with its challenges, and being a successful medical sales representative is no exception. Whether you’re an experienced sales rep and feel confi
by
Ruth Lynn
.png)
Teaser
Medical Affairs & ServicesContent Type
ArticlePublished
13/08/2024
Summary
Medical Affairs is a fast-paced sector and the work is so varied that no two days will look the same. Medical affairs professionals working in the pharmaceutical, biotechnology and medical device in

Teaser
Medical Affairs & ServicesContent Type
ArticlePublished
31/07/2024
Summary
At IQVIA, we recruit for various roles within the MedTech sphere and we’re always looking for professionals keen to move healthcare forward. In this article, we’ll outline the market for MedTech so
by
Tracey Smith

Teaser
MedicalContent Type
ArticlePublished
30/07/2024
Summary
In IQVIA, we support customers in their mission to get drugs to patients. As such, we recognise the value of keeping track of the latest market trends, developments, and insights. Modern healthcare
by
Catherine Scott

Teaser
Clinical OperationsContent Type
ArticlePublished
23/07/2024
Summary
Clinical pharmacology, a specialised branch of biomedical science, holds a pivotal role in developing vital drugs and ensuring their effective use in patients. Clinical pharmacologists bridge the ga
by
Ruth Lynn

Teaser
SalesContent Type
ArticlePublished
23/07/2024
Summary
Oncologists focus on diagnosing and treating cancer while overseeing treatment and managing post-treatment care. The oncology drugs market worldwide is expected to reach a market volume of $268bn by
by
Ruth Lynn

Teaser
GeneralContent Type
ArticlePublished
17/07/2024
Summary
Market access is all about preparing a drug for market entry, and as such it’s a vitally important part of the drug development process and wider pharmaceutical industry. While for pharmaceutical an
Recently viewed jobs